Table 2.

Proportion of women achieving an HIV viral load <50  copies/mL by treatment regimen at time of delivery.

	n ∗	HIV viral load <50  copies/mL  %   (95% CI)
All regimens	122	80.3%  (72.1–86.6%)
ATV 300/R throughout∗∗	101	83.2%  (74.3–89.4%)
ATV 400/R escalated∗∗∗	11	72.7%  (33.5–93.4%)
ATV 400 throughout†	7	50%  (11.0–89.0%)
ATV >400‡	2	100%  (15.8–100%)
ATV 400 (reduced to 300/R)§	1	100%  (2.5–100%)

*n: number of pregnancies in which women were taking the specified regimen at the time of delivery.

∗∗ATV 300/R throughout: women were prescribed atazanavir 300 mg/ritonavir 100 mg at all times when an atazanavir based regimen was prescribed in the recorded pregnancy.

∗∗∗ATV 400/R escalated: women prescribed atazanavir 300 mg/ritonavir 100 mg initially; then dose increased to atazanavir 400 mg/ritonavir 100 mg in the third trimester.

^†ATV 400 throughout: women prescribed atazanavir 400 mg without ritonavir throughout pregnancy.

^‡ATV >400 two pregnancies, both occurring in the same woman, where a dose of atazanavir >400 mg was prescribed without ritonavir boosting.

^§ATV 400 (reduced to 300/R): women prescribed atazanavir 400 mg without ritonavir at the start of pregnancy which was converted to atazanavir 300 mg/ritonavir 100 mg.